Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?
Le résumé fourni par la source
Rising CA-125 levels can detect relapsed ovarian cancer about six months before symptoms develop. Therefore, many asymptomatic patients have routine CA-125 measurements during follow-up. The only trial of CA-125 surveillance after first-line therapy randomized patients to early or delayed treatment after a doubling of CA-125 level. It showed those in the early arm had no survival benefit and worse quality of life. The trial was criticized as few patients had secondary surgery, yet randomized trials show conflicting results on the value surgery. Patients should be aware that recurrent ovarian cancer is not curable and require information on surveillance options.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Should CA-125 Surveillance be Performed after Completion of Primary Treatment for Ovarian Cancer Patients in Remission?
- Date Crossref
- 31/07/2023
- Éditeur
- Cambridge University Press
- Type
- book-chapter
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.